Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

But if not, you'll need to find stocks that hold the potential to pack more punch. The past doesn't predict the future, but ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

Allurion Technologies today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume ...